A team of experts has just launched Hong Kong’s first collaborative pharmacogenomics study using next-generation sequencing (NGS) technology to identify mutation targets in patients with treatment-resistant/relapsed ovarian cancer (OC) towards a more personalized approach in management.
Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.
Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.
Hereditary breast and ovarian cancer (HBOC) syndrome, which is primarily caused by BRCA1 and BRCA2 mutations, make up 8 to 10 percent of all breast cancers, says a senior consultant.
Identification of BRCA mutation in ovarian cancer is vital because it allows better risk management and there is evidence that carriers may benefit from new treatment modalities, said Professor Woo Yin Ling, consultant gynaecological oncologist at the University of Malaya.
Mode of delivery does not modify coeliac disease (CD) risk among infants born into at-risk families, report Italian researchers at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 2016 in Athens, Greece.